Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Corline Biomedical

16.85 SEK+3.06 %28.8, 9.13
Less than 1K followers

CLBIO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
+3.06 %
-4.80 %
-5.07 %
+6.31 %
+2.74 %
+34.26 %
+8.71 %
+7.67 %
+70.35 %

Corline Biomedical is active in the pharmaceutical industry. The company works with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The company sells its proprietary product CHS™ to medical technology customers, and is developing Renaparin® for use in regenerative medicine and organ transplantation. The headquarters are located in Uppsala.

Read more
Market cap
440.34M SEK
Turnover
6.41K SEK
Revenue
7.65M
EBIT %
-192.81 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16.11
2026

Interim report Q3'26

18.2
2027

Annual report '26

11.5
2027

Interim report Q1'27

Press release27.08.2026, 11.55

Redeye: Corline Biomedical (Q2 Review): Early stages of the Globe ramp-up

Corline Biomedical
Press release11.05.2026, 10.16

Redeye: Corline Biomedical (Q1 Review): Encouraging signs of commercial acceleration

Corline Biomedical
Press release18.02.2026, 11.21

Redeye: Corline Biomedical Q4 (Review): Case intact, but sales ramp-up needed to restore market confidence

Corline Biomedical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release19.11.2025, 08.25

Redeye: Corline Biomedical Q3 (Review) - Sales growth incoming

Corline Biomedical
Press release02.09.2025, 10.29

Redeye: Corline Biomedical - Kardium receives FDA approval

Corline Biomedical
Press release27.08.2025, 11.54

Redeye: Corline Biomedical Q2 - Kardium’s Globe system nearing launch

Corline Biomedical
Press release11.05.2025, 17.51

Redeye: Corline Biomedical Q1 - Exciting quarters ahead

Corline Biomedical
Press release18.02.2025, 08.34

Redeye: Corline Biomedical Q4 - Focus on Kardium’s market launch

Corline Biomedical
Press release04.02.2025, 07.47

Redeye: Redeye Initiates Coverage of Corline Biomedical

Corline Biomedical
Regulatory press release16.05.2019, 18.09

Corline Biomedical AB: Will present at investor event hosted by Aktiespararna on June 3rd in Stockholm

Corline Biomedical